Latest News of SMAP
Fulcrum Therapeutics Upgraded: BofA Debates Pivotal Study Success For Losmapimod In Rare Genetic Muscle Disease
By Yahoo! Finance |
2 months ago
BofA Securities upgraded Fulcrum Therapeutics ahead of phase 3 losmapimod readout for FSHD, a rare genetic muscle disease. The company's new study using the "reachable workspace" endpoint has sparked ...